Sagimet Biosciences Inc (NASDAQ:SGMT) has a beta value of 2.12 and has seen 1.31 million shares traded in the last trading session. The company, currently valued at $256.44M, closed the last trade at $8.36 per share which meant it lost -$0.36 on the day or -4.13%% during that session. The SGMT stock price is -14.83% off its 52-week high price of $9.60 and 79.31% above the 52-week low of $1.73. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.12 million shares traded. The 3-month trading volume is 1.37 million shares.
The consensus among analysts is that Sagimet Biosciences Inc (SGMT) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.49.
Sagimet Biosciences Inc (NASDAQ:SGMT) trade information
Sporting -4.13%% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SGMT stock price touched $8.36 or saw a rise of 10.59%. Year-to-date, Sagimet Biosciences Inc shares have moved 101.93%, while the 5-day performance has seen it change 35.06%. Over the past 30 days, the shares of Sagimet Biosciences Inc (NASDAQ:SGMT) have changed 143.73%. Short interest in the company has seen 3.66 million shares shorted with days to cover at 9.0.
Wall Street analysts have a consensus price target for the stock at $6, which means that the shares’ value could drop -39.33% from current levels. The projected low price target is $6.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is 28.23% off the targeted high while a plunge would see the stock lose 28.23% from current levels.
Sagimet Biosciences Inc (SGMT) estimates and forecasts
The company’s shares have gained 90.43% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -16.85% over the past 5 years. Earnings growth for 2025 is a modest -54.40% while over the next 5 years, the company’s earnings are expected to decrease by -25.74%.
SGMT Dividends
Sagimet Biosciences Inc is expected to release its next earnings report on 2025-May-08 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Sagimet Biosciences Inc (NASDAQ:SGMT)’s Major holders
Insiders own 8.40% of the company shares, while shares held by institutions stand at 45.88% with a share float percentage of 50.09%. Investors are also buoyed by the number of investors in a company, with Sagimet Biosciences Inc having a total of 87.0 institutions that hold shares in the company. The top two institutional holders are POINT72 ASSET MANAGEMENT, L.P. with over 2.37 million shares worth more than $8.09 million. As of 2024-06-30, POINT72 ASSET MANAGEMENT, L.P. held 7.414% of shares outstanding.
The other major institutional holder is NEA MANAGEMENT COMPANY, LLC, with the holding of over 2.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.84 million and represent 6.2677% of shares outstanding.
